Roche has announced recently that it intends to launch a high-volume SARS-CoV-2 Antigen test to aid in the diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. The test is planned to be made available at the end of 2020 for markets accepting the CE Mark. Roche also intends to file for Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).
The Elecsys SARS-CoV-2 Antigen test is a highly accurate laboratory immunoassay for the in vitro qualitative detection of the nucleocapsid antigen of SARS-CoV-2. The test is performed by healthcare professionals and uses nasopharyngeal or oropharyngeal swab samples from patients with signs and symptoms suggestive of Covid-19 or people with either known or suspected exposure SARS-CoV-2.
The Elecsys SARS-CoV-2 Antigen immunoassay runs on all Cobas e immunochemistry analyzers, widely available worldwide. These fully automated systems can provide test results in 18 minutes for a single test (excluding time for sample collection, transport, and preparation), with a throughput of up to 300 tests in an hour from a single analyzer, depending on the analyzer. A laboratory-based automated antigen assay allows for cost and error reduction due to the removal of manual handling and fast turn-around times, and high-test throughput.
Thomas Schinecker, chief executive officer, Roche Diagnostics, stated, “We are aware that governments and healthcare systems are under intense pressure to increase SARS-CoV-2 testing capacity to effectively manage the spread of the virus. A high-volume antigen test is a valuable addition to the testing portfolio for helping diagnose SARS-CoV-2 infection. Being able to quickly and correctly identify if someone has a SARS-CoV-2 infection is critical to informing patient management decisions and containing the spread of Covid-19. Roche remains committed to supporting governments, healthcare professionals and patients to fight this pandemic with the help of our diagnostics solutions.”
The test will be another addition to the comprehensive Roche diagnostic portfolio of solutions to help healthcare systems combat Covid-19 through testing in the laboratory and at the point of care. These solutions include both tests to detect an acute SARS-CoV-2 infection and tests measuring the body’s immune response upon infection or vaccination. The following table provides an overview of Roche’s current Covid-19 test portfolio for the detection of an acute SARS-CoV-2 infection or immune response:
*currently only available in CE markets